Highlights Xintela AB

Equities

XINT

SE0007756903

Delayed Nasdaq Stockholm Other stock markets 03:24:22 2024-04-30 am EDT			5-day change	1st Jan Change
0.294 ^SEK	+8.49%		+1.38%	+8.49%

Feb. 28	Xintela AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
Feb. 20	Xintela Names New Chief Scientific Officer	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Xintela AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Xintela AB Announces First Patient Dosed in It's Clinical Study on Difficult-To-Heal Leg Ulcers	Dec. 21	CI
Xintela Publishes Efficacy Results with EQSTEM from Preclinical Equine OA Study	Dec. 20	CI
Xintela AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 24	CI
Xintela's Stem Cell Product, Xstem, Assessed as Safe At All Dose Levels in Knee Osteoarthritis Clinical Study	23-10-13	CI
Xintela AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
Xintela Receives Product Patent in USA for Chondrocyte-Based Products	23-08-15	CI
Xintela Completes XSTEM Dosing at Third and Final Dose Level in Knee Osteoarthritis Clinical Study	23-06-22	CI
Xintela AB Announces Clinical Study with XSTEM for Knee Oeoarthritis Makes Good Progress	23-06-01	CI
Xintela AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Xintela AB Initiates Last Dose Level in Knee Osteoarthritis Study	23-05-02	CI
Xintela Starts Last Dose Level of Xstem in Knee Osteoarthritis Clinical Study	23-04-13	CI
Xintela AB Completes Dosing of XSTEM Second Dose Level in Knee Osteoarthritis Clinical Study	23-03-03	CI
Xintela AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-24	CI
Xintela and Northx Biologics Sign Collaboration Framework Agreement	22-12-14	CI
Xintela AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-25	CI
Xintela AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-25	CI
Targinta plans Phase 0 clinical study	22-11-24	AQ
Xintela Starts Next Dose Level of Xstem in Knee Osteoarthritis Clinical Study	22-11-09	CI
Xintela Completes Dosing of Xstem First Dose Level in Knee Osteoarthritis Clinical Study	22-09-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Xintela AB

Equities

XINT

SE0007756903

Highlights

Filters